INDIANAPOLIS, June 04, 2019 – Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Emgality (galcanezumab-gnlm) injection (300 mg) for the treatment of episodic cluster headache in…Original Article
FDA Approves Emgality (galcanezumab-gnlm) for the Treatment of Episodic Cluster Headache
